黄斑水肿-话题@MedSci

#黄斑水肿#

43篇内容 | 2226人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1510908, encodeId=71d5151090817, content=<a href='/topic/show?id=abd8103141b8' target=_blank style='color:#2F92EE;'>#黄斑水肿#</a>, objectTitle=BMC Ophthalmol：比较康柏西普和雷尼珠单抗治疗糖尿病性黄斑水肿12个月后的治疗效果！, objectType=article, longId=111160, objectId=6155111160b8, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=6155111160b8, replyNumber=0, likeNumber=77, createdTime=2017-08-30, rootId=0, userName=xiay994456, userId=8b9a10269982, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6155111160b8, moduleTitle=BMC Ophthalmol：比较康柏西普和雷尼珠单抗治疗糖尿病性黄斑水肿12个月后的治疗效果！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=6155111160b8)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1510907, encodeId=5697151090e98, content=<a href='/topic/show?id=abd8103141b8' target=_blank style='color:#2F92EE;'>#黄斑水肿#</a>, objectTitle=Ophthalmologica.：兰尼单抗对经激光治疗后的糖尿病性黄斑水肿（DME）具有良好疗效！, objectType=article, longId=106075, objectId=04641060e587, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=04641060e587, replyNumber=0, likeNumber=68, createdTime=2017-07-22, rootId=0, userName=xiay994456, userId=8b9a10269982, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=04641060e587, moduleTitle=Ophthalmologica.：兰尼单抗对经激光治疗后的糖尿病性黄斑水肿（DME）具有良好疗效！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=04641060e587)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1510906, encodeId=afe91510906d6, content=<a href='/topic/show?id=abd8103141b8' target=_blank style='color:#2F92EE;'>#黄斑水肿#</a>, objectTitle=Int Ophthalmol. ：关于视网膜分支静脉阻塞导致的黄斑水肿的三种不同的玻璃体内治疗模式的比较, objectType=article, longId=103336, objectId=291910333669, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=291910333669, replyNumber=0, likeNumber=49, createdTime=2017-06-27, rootId=0, userName=xiay994456, userId=8b9a10269982, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=291910333669, moduleTitle=Int Ophthalmol. ：关于视网膜分支静脉阻塞导致的黄斑水肿的三种不同的玻璃体内治疗模式的比较, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=291910333669)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1510905, encodeId=58901510905e6, content=<a href='/topic/show?id=abd8103141b8' target=_blank style='color:#2F92EE;'>#黄斑水肿#</a>, objectTitle=Ophthalmology.：美国眼科学会的一项关于与分支视网膜静脉阻塞相关的黄斑水肿的疗法的报告, objectType=article, longId=102365, objectId=342b10236537, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=342b10236537, replyNumber=0, likeNumber=74, createdTime=2017-06-20, rootId=0, userName=xiay994456, userId=8b9a10269982, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=342b10236537, moduleTitle=Ophthalmology.：美国眼科学会的一项关于与分支视网膜静脉阻塞相关的黄斑水肿的疗法的报告, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=342b10236537)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1510904, encodeId=297d151090497, content=<a href='/topic/show?id=abd8103141b8' target=_blank style='color:#2F92EE;'>#黄斑水肿#</a>, objectTitle=Ophthalmologica：糖尿病黄斑水肿患者的眼房水中可溶性血管内皮生长因子受体(sVEGFR)和炎症因子的水平显著高于非糖尿病人！, objectType=article, longId=100470, objectId=3fb01004e068, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=3fb01004e068, replyNumber=0, likeNumber=55, createdTime=2017-06-03, rootId=0, userName=xiay994456, userId=8b9a10269982, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=3fb01004e068, moduleTitle=Ophthalmologica：糖尿病黄斑水肿患者的眼房水中可溶性血管内皮生长因子受体(sVEGFR)和炎症因子的水平显著高于非糖尿病人！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=3fb01004e068)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1510903, encodeId=5fba1510903ba, content=<a href='/topic/show?id=abd8103141b8' target=_blank style='color:#2F92EE;'>#黄斑水肿#</a>, objectTitle=JAMA：视网膜中央静脉阻塞黄斑水肿贝伐单抗vs阿柏西普, objectType=article, longId=98373, objectId=4f88983e3a4, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=4f88983e3a4, replyNumber=0, likeNumber=93, createdTime=2017-05-12, rootId=0, userName=xiay994456, userId=8b9a10269982, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=4f88983e3a4, moduleTitle=JAMA：视网膜中央静脉阻塞黄斑水肿贝伐单抗vs阿柏西普, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=4f88983e3a4)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1510902, encodeId=321615109027b, content=<a href='/topic/show?id=abd8103141b8' target=_blank style='color:#2F92EE;'>#黄斑水肿#</a>, objectTitle=2015 NICE技术评估指南：阿柏西普治疗糖尿病性黄斑水肿（TA346）, objectType=article, longId=83778, objectId=4dcc83e787c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=4dcc83e787c, replyNumber=0, likeNumber=40, createdTime=2016-12-09, rootId=0, userName=xiay994456, userId=8b9a10269982, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=4dcc83e787c, moduleTitle=2015 NICE技术评估指南：阿柏西普治疗糖尿病性黄斑水肿（TA346）, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=4dcc83e787c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1510901, encodeId=78ff151090108, content=<a href='/topic/show?id=abd8103141b8' target=_blank style='color:#2F92EE;'>#黄斑水肿#</a>, objectTitle=【盘点】有关糖尿病性黄斑水肿研究进展汇总, objectType=article, longId=81041, objectId=e9e98104114, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e9e98104114, replyNumber=0, likeNumber=112, createdTime=2016-10-27, rootId=0, userName=xiay994456, userId=8b9a10269982, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e9e98104114, moduleTitle=【盘点】有关糖尿病性黄斑水肿研究进展汇总, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e9e98104114)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1510900, encodeId=c7c81510900cf, content=<a href='/topic/show?id=abd8103141b8' target=_blank style='color:#2F92EE;'>#黄斑水肿#</a>, objectTitle=2015NICE技术评估指南：玻璃体腔内注射地塞米松治疗糖尿病性黄斑水肿（TA349）发布, objectType=article, longId=81028, objectId=081881028be, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=081881028be, replyNumber=0, likeNumber=69, createdTime=2016-10-27, rootId=0, userName=xiay994456, userId=8b9a10269982, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=081881028be, moduleTitle=2015NICE技术评估指南：玻璃体腔内注射地塞米松治疗糖尿病性黄斑水肿（TA349）发布, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=081881028be)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1510899, encodeId=ecff1510899e2, content=<a href='/topic/show?id=abd8103141b8' target=_blank style='color:#2F92EE;'>#黄斑水肿#</a>, objectTitle=拜耳重磅眼科药物Eylea获英国NICE批准一线治疗视网膜分枝静脉阻塞(BRVO)继发黄斑水肿, objectType=article, longId=79465, objectId=df57e9465dc, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=df57e9465dc, replyNumber=0, likeNumber=34, createdTime=2016-10-09, rootId=0, userName=xiay994456, userId=8b9a10269982, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=df57e9465dc, moduleTitle=拜耳重磅眼科药物Eylea获英国NICE批准一线治疗视网膜分枝静脉阻塞(BRVO)继发黄斑水肿, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=df57e9465dc)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1510898, encodeId=f5a2151089897, content=<a href='/topic/show?id=abd8103141b8' target=_blank style='color:#2F92EE;'>#黄斑水肿#</a>, objectTitle=JAMA Ophthalmol：糖尿病性黄斑水肿选择什么药更划算？, objectType=article, longId=70510, objectId=02d9e051080, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=02d9e051080, replyNumber=0, likeNumber=59, createdTime=2016-06-13, rootId=0, userName=xiay994456, userId=8b9a10269982, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=02d9e051080, moduleTitle=JAMA Ophthalmol：糖尿病性黄斑水肿选择什么药更划算？, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=02d9e051080)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1510897, encodeId=3412151089e3a, content=<a href='/topic/show?id=abd8103141b8' target=_blank style='color:#2F92EE;'>#黄斑水肿#</a>, objectTitle=BMJ研究新闻：对于中重度糖尿病性黄斑水肿患者，阿柏西普的治疗效果优于贝伐单抗及雷珠单抗, objectType=article, longId=63953, objectId=41d26395382, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=41d26395382, replyNumber=0, likeNumber=65, createdTime=2016-03-02, rootId=0, userName=xiay994456, userId=8b9a10269982, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=41d26395382, moduleTitle=BMJ研究新闻：对于中重度糖尿病性黄斑水肿患者，阿柏西普的治疗效果优于贝伐单抗及雷珠单抗, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=41d26395382)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1510896, encodeId=ddb7151089610, content=<a href='/topic/show?id=abd8103141b8' target=_blank style='color:#2F92EE;'>#黄斑水肿#</a>, objectTitle=拜耳眼科药物Eylea视网膜静脉阻塞继发黄斑水肿（ME-RVO）新适应症获日本批准, objectType=article, longId=52572, objectId=bff4525e2dc, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=bff4525e2dc, replyNumber=0, likeNumber=67, createdTime=2015-07-01, rootId=0, userName=xiay994456, userId=8b9a10269982, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=bff4525e2dc, moduleTitle=拜耳眼科药物Eylea视网膜静脉阻塞继发黄斑水肿（ME-RVO）新适应症获日本批准, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=bff4525e2dc)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1510895, encodeId=16c61510895c0, content=<a href='/topic/show?id=abd8103141b8' target=_blank style='color:#2F92EE;'>#黄斑水肿#</a>, objectTitle=NEJM：玻璃体阿柏西普、贝伐单抗或兰尼单抗治疗糖尿病性黄斑水肿研究, objectType=article, longId=48809, objectId=620b488094a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=620b488094a, replyNumber=0, likeNumber=95, createdTime=2015-04-02, rootId=0, userName=xiay994456, userId=8b9a10269982, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=620b488094a, moduleTitle=NEJM：玻璃体阿柏西普、贝伐单抗或兰尼单抗治疗糖尿病性黄斑水肿研究, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=620b488094a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1510894, encodeId=5708151089462, content=<a href='/topic/show?id=abd8103141b8' target=_blank style='color:#2F92EE;'>#黄斑水肿#</a>, objectTitle=NGGZ：哌加他尼钠针对糖尿病黄斑水肿患者在日本进行III期临床研究, objectType=article, longId=43449, objectId=ff854344901, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ff854344901, replyNumber=0, likeNumber=0, createdTime=2014-12-01, rootId=0, userName=xiay994456, userId=8b9a10269982, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ff854344901, moduleTitle=NGGZ：哌加他尼钠针对糖尿病黄斑水肿患者在日本进行III期临床研究, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ff854344901)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1510893, encodeId=578c151089336, content=<a href='/topic/show?id=abd8103141b8' target=_blank style='color:#2F92EE;'>#黄斑水肿#</a>, objectTitle=Ophthalmology：aflibercept对糖尿病性黄斑水肿安全有效（VIVID-DME试验）, objectType=article, longId=38982, objectId=2b843898244, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=2b843898244, replyNumber=0, likeNumber=82, createdTime=2014-08-14, rootId=0, userName=xiay994456, userId=8b9a10269982, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2b843898244, moduleTitle=Ophthalmology：aflibercept对糖尿病性黄斑水肿安全有效（VIVID-DME试验）, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=2b843898244)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1510892, encodeId=ebf8151089286, content=<a href='/topic/show?id=abd8103141b8' target=_blank style='color:#2F92EE;'>#黄斑水肿#</a>, objectTitle=Ophthalmology：Eylea能持续改善糖尿病性黄斑水肿（DME）患者视力, objectType=article, longId=38151, objectId=f83538151ff, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f83538151ff, replyNumber=0, likeNumber=105, createdTime=2014-07-25, rootId=0, userName=xiay994456, userId=8b9a10269982, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f83538151ff, moduleTitle=Ophthalmology：Eylea能持续改善糖尿病性黄斑水肿（DME）患者视力, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f83538151ff)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1510891, encodeId=dba015108912a, content=<a href='/topic/show?id=abd8103141b8' target=_blank style='color:#2F92EE;'>#黄斑水肿#</a>, objectTitle=拜耳Eylea 2个III期糖尿病性黄斑水肿试验均达主要终点, objectType=article, longId=22742, objectId=237922e4273, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=237922e4273, replyNumber=0, likeNumber=56, createdTime=2013-08-09, rootId=0, userName=xiay994456, userId=8b9a10269982, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=237922e4273, moduleTitle=拜耳Eylea 2个III期糖尿病性黄斑水肿试验均达主要终点, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=237922e4273)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1510890, encodeId=8063151089092, content=<a href='/topic/show?id=abd8103141b8' target=_blank style='color:#2F92EE;'>#黄斑水肿#</a>, objectTitle=CHMP建议批准拜耳Eylea用于视网膜中央静脉阻塞(CRVO)继发黄斑水肿（ME）, objectType=article, longId=22426, objectId=41c4224261a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=41c4224261a, replyNumber=0, likeNumber=0, createdTime=2013-08-02, rootId=0, userName=xiay994456, userId=8b9a10269982, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=41c4224261a, moduleTitle=CHMP建议批准拜耳Eylea用于视网膜中央静脉阻塞(CRVO)继发黄斑水肿（ME）, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=41c4224261a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1510889, encodeId=00851510889d2, content=<a href='/topic/show?id=abd8103141b8' target=_blank style='color:#2F92EE;'>#黄斑水肿#</a>, objectTitle=Diabetes Care:微动脉瘤更替预测临床意义黄斑水肿, objectType=article, longId=12939, objectId=38c41293999, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=38c41293999, replyNumber=0, likeNumber=72, createdTime=2012-12-14, rootId=0, userName=xiay994456, userId=8b9a10269982, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=38c41293999, moduleTitle=Diabetes Care:微动脉瘤更替预测临床意义黄斑水肿, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=38c41293999)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

黄斑水肿

2020-05-29

xiay994456 (审核中...)

前往app查看评论内容

#黄斑水肿#

BMC Ophthalmol：比较康柏西普和雷尼珠单抗治疗糖尿病性黄斑水肿12个月后的治疗效果！

2017-08-30

xiay994456 (审核中...)

前往app查看评论内容

#黄斑水肿#

Ophthalmologica.：兰尼单抗对经激光治疗后的糖尿病性黄斑水肿（DME）具有良好疗效！

2017-07-22

xiay994456 (审核中...)

前往app查看评论内容

#黄斑水肿#

Int Ophthalmol. ：关于视网膜分支静脉阻塞导致的黄斑水肿的三种不同的玻璃体内治疗模式的比较

2017-06-27

xiay994456 (审核中...)

前往app查看评论内容

#黄斑水肿#

Ophthalmology.：美国眼科学会的一项关于与分支视网膜静脉阻塞相关的黄斑水肿的疗法的报告

2017-06-20

xiay994456 (审核中...)

前往app查看评论内容

#黄斑水肿#

Ophthalmologica：糖尿病黄斑水肿患者的眼房水中可溶性血管内皮生长因子受体(sVEGFR)和炎症因子的水平显著高于非糖尿病人！

2017-06-03

xiay994456 (审核中...)

前往app查看评论内容

#黄斑水肿#

JAMA：视网膜中央静脉阻塞黄斑水肿贝伐单抗vs阿柏西普

2017-05-12

xiay994456 (审核中...)

前往app查看评论内容

#黄斑水肿#

2015 NICE技术评估指南：阿柏西普治疗糖尿病性黄斑水肿（TA346）

2016-12-09

xiay994456 (审核中...)

前往app查看评论内容

#黄斑水肿#

【盘点】有关糖尿病性黄斑水肿研究进展汇总

2016-10-27

xiay994456 (审核中...)

前往app查看评论内容

#黄斑水肿#

2015NICE技术评估指南：玻璃体腔内注射地塞米松治疗糖尿病性黄斑水肿（TA349）发布

2016-10-27

xiay994456 (审核中...)

前往app查看评论内容

#黄斑水肿#

拜耳重磅眼科药物Eylea获英国NICE批准一线治疗视网膜分枝静脉阻塞(BRVO)继发黄斑水肿

2016-10-09

xiay994456 (审核中...)

前往app查看评论内容

#黄斑水肿#

JAMA Ophthalmol：糖尿病性黄斑水肿选择什么药更划算？

2016-06-13

xiay994456 (审核中...)

前往app查看评论内容

#黄斑水肿#

BMJ研究新闻：对于中重度糖尿病性黄斑水肿患者，阿柏西普的治疗效果优于贝伐单抗及雷珠单抗

2016-03-02

xiay994456 (审核中...)

前往app查看评论内容

#黄斑水肿#

拜耳眼科药物Eylea视网膜静脉阻塞继发黄斑水肿（ME-RVO）新适应症获日本批准

2015-07-01

xiay994456 (审核中...)

前往app查看评论内容

#黄斑水肿#

NEJM：玻璃体阿柏西普、贝伐单抗或兰尼单抗治疗糖尿病性黄斑水肿研究

2015-04-02

xiay994456 (审核中...)

前往app查看评论内容

#黄斑水肿#

NGGZ：哌加他尼钠针对糖尿病黄斑水肿患者在日本进行III期临床研究

2014-12-01

xiay994456 (审核中...)

前往app查看评论内容

#黄斑水肿#

Ophthalmology：aflibercept对糖尿病性黄斑水肿安全有效（VIVID-DME试验）

2014-08-14

xiay994456 (审核中...)

前往app查看评论内容

#黄斑水肿#

Ophthalmology：Eylea能持续改善糖尿病性黄斑水肿（DME）患者视力

2014-07-25

xiay994456 (审核中...)

前往app查看评论内容

#黄斑水肿#

拜耳Eylea 2个III期糖尿病性黄斑水肿试验均达主要终点

2013-08-09

xiay994456 (审核中...)

前往app查看评论内容

#黄斑水肿#

CHMP建议批准拜耳Eylea用于视网膜中央静脉阻塞(CRVO)继发黄斑水肿（ME）

2013-08-02

xiay994456 (审核中...)

前往app查看评论内容

#黄斑水肿#

Diabetes Care:微动脉瘤更替预测临床意义黄斑水肿

2012-12-14

科室
- - 订阅+
  - 更多科室
工具
服务